PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors
The immunological surveillance of tumors relies on a specific recognition of cancer cells and their associate antigens by leucocytes of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure in cell-cell recognition, thus, allowin...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/947858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563941786517504 |
|---|---|
| author | Francesco Dituri Antonio Mazzocca Gianluigi Giannelli Salvatore Antonaci |
| author_facet | Francesco Dituri Antonio Mazzocca Gianluigi Giannelli Salvatore Antonaci |
| author_sort | Francesco Dituri |
| collection | DOAJ |
| description | The immunological surveillance of tumors relies on a specific recognition of cancer cells and their associate antigens by leucocytes of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure in cell-cell recognition, thus, allowing cancer cells to evade the killing system. The phosphatidylinositol 3-kinase (PI3K) pathway regulates multiple cellular processes which underlie immune responses against pathogens or malignant cells. Conversely, there is accumulating evidence that the PI3K pathway is involved in the development of several malignant traits of cancer cells as well as their escape from immunity. Herein, we review the counteracting roles of PI3K not only in antitumor immune response but also in the mechanisms that cancer cells use to avoid leukocyte attack. In addition, we discuss, from antitumor immunological point of view, the potential benefits and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway. |
| format | Article |
| id | doaj-art-d1f9407482e54153a4fb86452b41db66 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-d1f9407482e54153a4fb86452b41db662025-02-03T01:12:17ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/947858947858PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by TumorsFrancesco Dituri0Antonio Mazzocca1Gianluigi Giannelli2Salvatore Antonaci3Department of Emergency and Organ Transplantation, Section of Internal Medicine, Allergology and Clinical Immunology, University of Bari Medical School, 70124 Bari, ItalyDepartment of Emergency and Organ Transplantation, Section of Internal Medicine, Allergology and Clinical Immunology, University of Bari Medical School, 70124 Bari, ItalyDepartment of Emergency and Organ Transplantation, Section of Internal Medicine, Allergology and Clinical Immunology, University of Bari Medical School, 70124 Bari, ItalyDepartment of Emergency and Organ Transplantation, Section of Internal Medicine, Allergology and Clinical Immunology, University of Bari Medical School, 70124 Bari, ItalyThe immunological surveillance of tumors relies on a specific recognition of cancer cells and their associate antigens by leucocytes of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure in cell-cell recognition, thus, allowing cancer cells to evade the killing system. The phosphatidylinositol 3-kinase (PI3K) pathway regulates multiple cellular processes which underlie immune responses against pathogens or malignant cells. Conversely, there is accumulating evidence that the PI3K pathway is involved in the development of several malignant traits of cancer cells as well as their escape from immunity. Herein, we review the counteracting roles of PI3K not only in antitumor immune response but also in the mechanisms that cancer cells use to avoid leukocyte attack. In addition, we discuss, from antitumor immunological point of view, the potential benefits and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway.http://dx.doi.org/10.1155/2011/947858 |
| spellingShingle | Francesco Dituri Antonio Mazzocca Gianluigi Giannelli Salvatore Antonaci PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors Clinical and Developmental Immunology |
| title | PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors |
| title_full | PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors |
| title_fullStr | PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors |
| title_full_unstemmed | PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors |
| title_short | PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors |
| title_sort | pi3k functions in cancer progression anticancer immunity and immune evasion by tumors |
| url | http://dx.doi.org/10.1155/2011/947858 |
| work_keys_str_mv | AT francescodituri pi3kfunctionsincancerprogressionanticancerimmunityandimmuneevasionbytumors AT antoniomazzocca pi3kfunctionsincancerprogressionanticancerimmunityandimmuneevasionbytumors AT gianluigigiannelli pi3kfunctionsincancerprogressionanticancerimmunityandimmuneevasionbytumors AT salvatoreantonaci pi3kfunctionsincancerprogressionanticancerimmunityandimmuneevasionbytumors |